Applied Cognition

Applied Cognition is pioneering a novel therapeutic approach focused on enhancing the brain's glymphatic waste clearance system to treat neurodegenerative diseases. Its core asset is a proprietary, non-invasive measurement platform that has identified targets and led to a lead small molecule combination candidate, ACX-02, which has shown early biomarker evidence of clearing amyloid and tau. The company is leveraging its platform for ongoing target discovery and drug development, positioning itself at the intersection of neuroscience, physiology, and potential AI-driven insights.

Proprietary non-invasive platform for continuous, real-time measurement of glymphatic function in humans. It simultaneously assesses three key physiologies: sleep EEG state, cerebral vascular function, and astrocyte regulation of interstitial resistance. Used for target discovery, drug screening, and biomarker assessment.

Competition includes approved anti-amyloid monoclonal antibodies (e.g., Leqembi, Kisunla) and anti-tau therapies in development, which are typically single-target. Other approaches targeting neuroinflammation or protein clearance pathways exist. Applied Cognition's key differentiation is its oral, small molecule combination aimed at enhancing the endogenous, multi-protein clearance system via a proprietary measurement platform.